|Bid||115.52 x 100|
|Ask||133.50 x 100|
|Day's Range||132.88 - 136.97|
|52 Week Range||75.52 - 153.15|
|PE Ratio (TTM)||-237.23|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Gilead Sciences, Inc.'s revenue is estimated to decline by just over 18% when it reports its Q2 results.
Eli Lilly and Incyte gave an update on rheumatoid arthritis drug baricitinib as Lilly unveiled second-quarter numbers that surpassed analyst estimates.
A delay in getting its rheumatoid arthritis drug to market by at least 18 months sent Eli Lilly shares lower Tuesday.